Internal Medicine, Hematology & Oncology · Redding, CA
NPI
1225094469
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
2145 Court St
Redding, CA, 96001
Phone (530) 247-1425
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.7M
354,220 services
Medicare patients, 2024
770
Average age 75
Drug cost, 2024
$2.8M
1,143 prescriptions
Company payments, 2025
$970
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Promila Dhanuka was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 119,341 times for 88 patients. In total Promila Dhanuka billed 354,220 services in 91 codes, and Medicare paid $2.7M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-05-16.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 119,341 | 88 | $0.27 | $33K |
| Q5101 Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 41,880 | 18 | $0.26 | $11K |
| J9267 Injection, paclitaxel, 1 mg | Office | 19,870 | 15 | $0.08 | $1,581 |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 11,000 | 12 | $9.05 | $100K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 8,800 | 13 | $33.90 | $298K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 8,251 | 147 | $0.09 | $744 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 4,075 | 63 | $0.07 | $301 |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 3,800 | 26 | $5.78 | $22K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 3,600 | 12 | $0.11 | $395 |
| J0897 Injection, denosumab, 1 mg | Office | 3,600 | 25 | $20.67 | $74K |
| Q5115 Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | Office | 3,540 | 13 | $25.26 | $89K |
| 99214 Office E&M - Established | Office | 2,524 | 654 | $95.40 | $241K |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 801 | 145 | $0.65 | $522 |
| 96367 Intravenous Infusion, Hydration | Office | 757 | 137 | $23.59 | $18K |
| J9045 Injection, carboplatin, 50 mg | Office | 750 | 18 | $2.45 | $1,836 |
By year: 2022 $980K for 166,876 services; 2023 $1.9M for 251,685 services; 2024 $2.7M for 354,220 services.
Medicare prescription drug claims, 2024
In 2024, the drug Promila Dhanuka prescribed most often to Medicare patients was Anastrozole, with 159 prescriptions and refills. In total Promila Dhanuka wrote 1,143 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 159 | 215 | 34 | $1,639 |
| Allopurinol Generic | 138 | 202 | 29 | $781 |
| Hydroxyurea Generic | 112 | 146 | 17 | $1,495 |
| Ondansetron Hcl Generic | 92 | 92 | 48 | $6,004 |
| Prochlorperazine Maleate Generic | 82 | 82 | 54 | $2,249 |
| Imbruvica Ibrutinib | 45 | 45 | Under 11 | $734K |
| Anagrelide Hcl Generic | 34 | 67 | Under 11 | $12K |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 33 | 33 | 29 | $397 |
| Dexamethasone Generic | 31 | 31 | Under 11 | $948 |
| Jakafi Ruxolitinib Phosphate | 25 | 25 | Under 11 | $403K |
| Lenalidomide Generic | 25 | 25 | Under 11 | $379K |
| Letrozole Generic | 23 | 39 | Under 11 | $324 |
| Imatinib Mesylate Generic | 23 | 25 | Under 11 | $8,118 |
| Ciprofloxacin Hcl Generic | 21 | 21 | 21 | $65.33 |
| Prednisone Generic | 20 | 20 | Under 11 | $105 |
Brand drugs: 176 claims; generic drugs: 967 claims; opioid claims: 20.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Promila Dhanuka $970 ($970 in general payments such as food, travel and fees) from 19 companies. The largest payer was Daiichi Sankyo Inc. with $247.
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. 4568.T | 17 | $247 |
| Janssen Biotech, Inc. JNJ | 4 | $93.97 |
| Pfizer Inc. PFE | 4 | $86.16 |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $66.13 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $56.53 |
| Abbvie Inc. ABBV | 2 | $47.02 |
| Incyte Corporation INCY | 2 | $45.7 |
| Rigel Pharmaceuticals, Inc. RIGL | 2 | $41.29 |
| Geron Corporation GERN | 1 | $33.28 |
| Astellas Pharma US Inc 4503.T | 1 | $31.49 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.